Journal article
Orbital decompression surgery among Medicare beneficiaries in the post‐teprotumumab era
International forum of allergy & rhinology, v 14(9), pp 1505-1509
Sep 2024
PMID: 38716766
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Key points Utilization of orbital decompressions (ODS) increased (CAGR: +3.2%) from 2000 to 2019. FDA approved teprotumumab in January 2020; ODS utilization decreased (CAGR: −14.9%) from 2019 to 2022. In 2022, total spending was substantially higher for teprotumumab ( $325 million) than surgery ($ 580,000).
Metrics
1 Record Views
Details
- Title
- Orbital decompression surgery among Medicare beneficiaries in the post‐teprotumumab era
- Creators
- Akash M. Bhat - Medical University of South CarolinaZachary M. Soler - Medical University of South CarolinaRodney J. Schlosser - Medical University of South CarolinaRalph B. Metson - Massachusetts Eye and Ear InfirmaryVinay K. Rathi - The Ohio State University
- Publication Details
- International forum of allergy & rhinology, v 14(9), pp 1505-1509
- Publisher
- Wiley
- Number of pages
- 5
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Neurosurgery
- Web of Science ID
- WOS:001215449700001
- Scopus ID
- 2-s2.0-85192388701
- Other Identifier
- 991022202489704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Otorhinolaryngology